MARKET

RDUS

RDUS

Radius Health
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.46
-0.34
-2.66%
Opening 11:23 09/20 EDT
OPEN
12.57
PREV CLOSE
12.80
HIGH
12.68
LOW
12.42
VOLUME
60.54K
TURNOVER
--
52 WEEK HIGH
26.16
52 WEEK LOW
10.15
MARKET CAP
588.94M
P/E (TTM)
-9.7071
1D
5D
1M
3M
1Y
5Y
Radius Health Earnings Perspective: Return On Capital Employed
According to Benzinga Pro data, during Q2, Radius Health (NASDAQ:RDUS) posted sales of $51.80 million. Earnings were up 11.28%, but Radius Health still reported an overall loss of $11.89 million.
Benzinga · 09/07 15:30
Birch Grove Capital LP Buys Churchill Capital Corp V, Spirit AeroSystems Holdings Inc, Flexion ...
GuruFocus News · 08/18 20:38
Rubric Capital Management LP Buys Golar LNG, Arconic Corp, Karyopharm Therapeutics Inc, Sells ...
GuruFocus News · 08/17 16:38
Loss-Making Radius Health, Inc. (NASDAQ:RDUS) Expected To Breakeven In The Medium-Term
We feel now is a pretty good time to analyse Radius Health, Inc.'s ( NASDAQ:RDUS ) business as it appears the company...
Simply Wall St. · 08/09 13:46
Radius (RDUS) Q2 Loss Narrower Than Expected, Revenues Lag
Zacks.com · 08/06 15:26
--SVB Leerink Adjusts Radius Health's Price Target to $26 from $24, Keeps Market Perform Rating
MT Newswires · 08/06 13:14
HC Wainwright & Co. Maintains Neutral on Radius Health, Lowers Price Target to $19
HC Wainwright & Co. analyst Douglas Tsao maintains Radius Health (NASDAQ:RDUS) with a Neutral and lowers the price target from $25 to $19.
Benzinga · 08/06 10:16
SVB Leerink Maintains Market Perform on Radius Health, Raises Price Target to $26
SVB Leerink analyst Geoffrey Porges maintains Radius Health (NASDAQ:RDUS) with a Market Perform and raises the price target from $24 to $26.
Benzinga · 08/06 09:54
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RDUS. Analyze the recent business situations of Radius Health through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RDUS stock price target is 22.14 with a high estimate of 31.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 204
Institutional Holdings: 60.82M
% Owned: 128.67%
Shares Outstanding: 47.27M
TypeInstitutionsShares
Increased
46
1.40M
New
13
459.79K
Decreased
43
1.64M
Sold Out
22
619.63K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.57%
Pharmaceuticals & Medical Research
-0.46%
Key Executives
Non-Executive Chairman/Independent Director
Owen Hughes
President/Chief Executive Officer/Director
G. Kelly Martin
Chief Financial Officer/Chief Accounting Officer/Treasurer
Steven Helwig
Senior Vice President
Salvador Grausso
Senior Vice President
Chhaya Shah
Independent Director
Willard Dere
Independent Director
Catherine Friedman
Independent Director
Jean-Pierre Garnier
Independent Director
Sean Murphy
Independent Director
Machelle Sanders
Independent Director
Andrew Von Eschenbach
No Data
  • All
  • Financials
  • Insiders
More
About RDUS
Radius Health, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing endocrine therapeutics. Its lead product, TYMLOS (abaloparatide) injection, is a prescription medicine for the treatment of postmenopausal women with osteoporosis at high risk for fracture. It also has products in clinical pipeline, which includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group, and RAD011, a synthetic cannabidiol oral solution that is being developed for the treatment of Prader-Willi syndrome (PWS).

Webull offers kinds of Radius Health Inc stock information, including NASDAQ:RDUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RDUS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RDUS stock methods without spending real money on the virtual paper trading platform.